Histrelin

At a glance

Overview

Histrelin illustrates how continuous exposure to a hormone agonist can ultimately suppress the pathway it first stimulates. Supprelin LA releases histrelin from an implant placed under the skin and is used for central precocious puberty, where the hypothalamic-pituitary-gonadal axis becomes active unusually early. Treatment aims include slowing pubertal progression and excessive advancement of bone age. Implant placement and removal are clinical procedures, and biochemical response and growth require follow-up. The separate prostate-cancer implant Vantas is listed as discontinued in current FDA records; its historical indication should not be substituted for the current pediatric implant label.

Supporting sources [1] [2] [3]

How it works

Following an initial increase in LH, FSH and sex steroids, continuous histrelin exposure desensitizes the pituitary response to GnRH. Lower gonadotropin output reduces ovarian estrogen and testicular testosterone production. In central precocious puberty, this suppresses the early activation of the normal pubertal pathway. It does not address every cause of early sexual development, which is why hormone-independent disorders must be distinguished during diagnosis.

Supporting sources [1] [2] [3]

Why must the cause of early puberty be confirmed?

Central precocious puberty results from premature activation of the GnRH pathway. The label requires a diagnostic evaluation that includes hormone testing and bone-age assessment, with imaging or additional tests as appropriate. Histrelin does not automatically treat hormone secretion arising independently from the pituitary pathway.

Supporting sources [1]

What did the pediatric trial show?

A prospective multicenter study enrolled 36 children and evaluated a histrelin implant over one year. Stimulated LH and sex-steroid concentrations were strongly suppressed, supporting the treatment’s endocrine effect. Longer-term growth and clinical follow-up remain important because hormone suppression is not identical to a guaranteed adult-height outcome.

Supporting sources [2]

What monitoring and procedure risks matter?

An early hormonal flare can transiently increase pubertal symptoms. The implant can be difficult to locate or remove and may break, requiring confirmation that all fragments are removed. Label warnings also address psychiatric symptoms, convulsions, severe skin reactions and pediatric intracranial hypertension.

Supporting sources [1]

Does an implant mean treatment can be left unattended?

No. The labeled pathway includes planned follow-up, assessment of LH and sex-steroid suppression, and tracking of growth and bone age. Placement and removal require appropriate procedural care. A long-acting formulation changes delivery convenience, not the need to verify that treatment is achieving its intended effect.

Supporting sources [1]

Is the adult Vantas implant still marketed?

Current FDA records list Vantas as discontinued. This is a separate presentation from Supprelin LA, which remains labeled for central precocious puberty. The historical adult oncology indication does not make the pediatric implant an interchangeable prostate-cancer product; formulation, availability and the applicable label must be distinguished.

Supporting sources [1] [3]